Hosted on MSN5d
A new weight loss pill outperformed Novo Nordisk's version
William Blair analyst Andy Hsieh noted on Monday that Viking’s results surpassed Wall Street expectations and outperformed ...
How does Viking's weight loss med compare to ones from Novo, Eli Lilly?
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
Novo Nordisk A/S (NYSE:NVO) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...
Yahoo5d
A new weight loss pill outperformed Novo Nordisk's version
“Notably, the 100 mg dose appears to be outpacing the 100 mg dose of amycretin, which achieved about a 5% placebo-adjusted weight loss in four weeks,” Hsieh wrote. Novo Nordisk stock fell ...
Viking Therapeutics Offers An Obesity Drug for Healthy Adults
Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...
pharmaphorum2d
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...